Abstract:The discovery of novel therapeutic compounds through de novo drug design represents a critical challenge in the field of pharmaceutical research. Traditional drug discovery approaches are often resource intensive and time consuming, leading researchers to explore innovative methods that harness the power of deep learning and reinforcement learning techniques. Here, we introduce a novel drug design approach called drugAI that leverages the Encoder–Decoder Transformer architecture in tandem with Reinforcement Learning via a Monte Carlo Tree Search (RL-MCTS) to expedite the process of drug discovery while ensuring the production of valid small molecules with drug-like characteristics and strong binding affinities towards their targets. We successfully integrated the Encoder–Decoder Transformer architecture, which generates molecular structures (drugs) from scratch with the RL-MCTS, serving as a reinforcement learning framework. The RL-MCTS combines the exploitation and exploration capabilities of a Monte Carlo Tree Search with the machine translation of a transformer-based Encoder–Decoder model. This dynamic approach allows the model to iteratively refine its drug candidate generation process, ensuring that the generated molecules adhere to essential physicochemical and biological constraints and effectively bind to their targets. The results from drugAI showcase the effectiveness of the proposed approach across various benchmark datasets, demonstrating a significant improvement in both the validity and drug-likeness of the generated compounds, compared to two existing benchmark methods. Moreover, drugAI ensures that the generated molecules exhibit strong binding affinities to their respective targets. In summary, this research highlights the real-world applications of drugAI in drug discovery pipelines, potentially accelerating the identification of promising drug candidates for a wide range of diseases.

Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators

Combining generative artificial intelligence and on-chip synthesis for de novo drug design

Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound

De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search

Artificial Intelligence in De novo Drug Design: Are We Still There?

REINVENT 2.0: An AI Tool for De Novo Drug Design

Prospective de novo drug design with deep interactome learning

De novo generation of dual-target ligands using adversarial training and reinforcement learning

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

De Novo Structure-Based Drug Design Using Deep Learning

RetroGNN: Fast Estimation of Synthesizability for Virtual Screening and De Novo Design by Learning from Slow Retrosynthesis Software

Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4

Deep learning approaches for <i>de novo</i> drug design: An overview

Advances in De Novo Drug Design: From Conventional to Machine Learning Methods

De Novo Design of Nurr1 Agonists via Fragment-Augmented Generative Deep Learning in Low-Data Regime

Molecular De Novo Design through Deep Reinforcement Learning

Transformer-Based Generative Model Accelerating the Development of Novel BRAF Inhibitors

Artifical intelligence: a virtual chemist for natural product drug discovery

Status and Prospects of Research on Deep Learning-based De Novo Generation of Drug Molecules

CNSMolGen: a bidirectional recurrent neural networks based generative model for de novo central nervous system drug design

SynthFormer: Equivariant Pharmacophore-based Generation of Molecules for Ligand-Based Drug Design